Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that tildacerfont treatment in males with congenital adrenal hyperplasia reduced androgen levels and improved markers of testicular function, suggesting potential benefits for male reproductive health.

In this study, researchers reported that the SHBG +5790 G>A polymorphism was associated with an increased risk of developing resistance to hormonal castration in advanced prostate cancer patients.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This review discusses differences in ERβ signaling between rodents and humans and reports no new clinical results; the authors highlight the need for further research in humans before using ERβ agonists clinically.

In this review, the researchers reported that 5α-reductase inhibitors demonstrated neuroprotective effects and reduced dyskinesias in animal models of Parkinson's disease, suggesting their potential for repurposing to manage symptoms in men with PD.

This rat study suggests that 5α-dihydrotestosterone plays a critical role in inhibiting nipple development in male fetuses by causing the regression of the nipple anlage in utero.

This study suggests that synthetic steroid analogues or 5α-reductase modulation could be potential therapeutic strategies for nervous system disorders, but further research on their effects is necessary.

This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.

This study analyzed the FDA Adverse Event Reporting System and found distinct safety signals and adverse event patterns among α1-blockers, 5α-reductase inhibitors, and tadalafil used in treating benign prostatic hyperplasia, emphasizing known risks and identifying potential new ones that require further study.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This study analyzed 3,295 cases from the FDA Adverse Event Reporting System to describe demographics and reporting trends of post-finasteride syndrome, finding that most reports came from patients rather than health professionals.

This review discusses alternative androgen pathways, including the "backdoor" pathway and pathways to 11-oxygenated steroids, and reports no new clinical results; the authors aim to clarify these concepts for better patient treatment.

In this study, researchers found that young men with androgenic alopecia exhibited significantly higher mRNA levels of 5α-reductase isozymes and changes in prostate cancer-related genes, which could explain varying responses to treatment and guide future therapies.

This review analyzed current research on finasteride and dutasteride and found insufficient evidence to fully elucidate their role in metabolic adverse events, such as liver disease and diabetes, due to a lack of detailed pathophysiologic understanding; further studies are needed to clarify these mechanisms.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

This study found that finasteride significantly suppresses serum dihydrotestosterone levels at all tested doses in normal male volunteers without significant adverse effects.

In this study using a virtual screening approach, eriocitrin and silymarin were identified as potent flavonoid compounds that strongly and stably interacted with 5α-reductase type II, suggesting potential development as novel treatments for androgenic alopecia.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study found that individuals in this Egyptian cohort carrying the leucine (L) allele of the 5-α reductase type II enzyme had a higher risk of developing androgenetic alopecia, which may be associated with oxidative stress.

This study found that two novel nonsteroidal derivatives inhibited specific enzymes in vitro and in vivo, leading to dihydrotestosterone accumulation in androgen-dependent glands, suggesting potential therapeutic use for mood improvement in the elderly.

This study found that dutasteride affected spinal bone formation in curdlan-treated SKG mice, while DHT treatment reduced osteoblast differentiation in vitro, suggesting that DHT inhibition might unexpectedly increase spinal ankylosis progression in ankylosing spondylitis patients.

This commentary notes that 5-alpha reductase inhibitors have successfully treated benign prostatic hyperplasia and androgenetic alopecia but reports no new findings.

This study found that both Finasteride and MK386 reduced cell proliferation in primary prostate cancer cultures, with Finasteride being more effective in lower Gleason scores and MK386 in higher ones.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

Saw palmetto extract can block the enzyme that converts testosterone in pig prostate cells.

Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.

This study reported that administering finasteride reduced levels of certain neuroactive androgens in rat brains, suggesting peripheral origin for most 3α,5α-Adiol and brain synthesis for 3α,5α-A.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.